Search / 2842 results found

from
to
  • Updated

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences:

  • Updated

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- The Harvard Center for Green Buildings and Cities (CGBC) at the Graduate School of Design has just published "Zero-carbon Balance: The Case of HouseZero," the first full accounting of the structure's embodied carbon and a detailed methodology behind calculating its zero-carbon balance in the peer-reviewed journal Building and Environment. In tandem, the CGBC has also released a summary of the lab's full-year performance results.

  • Updated

BOSTON, Nov. 24, 2021 /PRNewswire/ -- Are you fed up with Zoom? Do you want online interactions to feel more… interactive? The metaverse promises a step-change in how society communicates but, without the hardware technology, will ultimately remain a pipe dream.

  • Updated

BOSTON, Nov. 24, 2021 /PRNewswire/ -- Are you fed up with Zoom? Do you want online interactions to feel more… interactive? The metaverse promises a step-change in how society communicates but, without the hardware technology, will ultimately remain a pipe dream.

  • Updated

BOSTON, Nov. 24, 2021 /PRNewswire/ -- Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing. This financing round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred Capital, and Elikon Venture. Existing investors - TF Capital and Med-Fine Capital - continued to support in this round.